Evidence map›Paper›PMID 39514041›Full record

Trial reportAdvances in therapy2025

Effect of Tezepelumab on Sino-Nasal Outcome Test (SNOT)-22 Domain and Symptom-Specific Scores in Patients with Severe, Uncontrolled Asthma and a History of Chronic Rhinosinusitis with Nasal Polyps.

Joshua S Jacobs, Joseph K Han, Jason K Lee, Tanya M Laidlaw, Nicole L Martin, Scott Caveney, Christopher S Ambrose, Neil Martin, Joseph D Spahn, Flavia C L Hoyte

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03347279 (A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma), which is not on this map. Cited by 15 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03347279 phase3completednot on this map

A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (NAVIGATOR)

TypeinterventionalSponsorAstraZenecaRan2017 to 2020Enrolled1,061ConditionsAsthmaArmsExperimental: Tezepelumab, Placebo
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Efficacy of tezepelumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Joshua S JacobsAllergy and Asthma Clinical Research, 370 North Widget Lane, Suite 210, Walnut Creek, CA, 94598, USA. jjacobs@bayareaallergy.com.ORCID 0000-0001-7748-6887
Joseph K HanDepartment of Otolaryngology & Head & Neck Surgery, Eastern Virginia Medical School, Norfolk, VA, USA.
Jason K LeeEvidence Based Medical Educator Inc., Toronto, ON, Canada.
Tanya M LaidlawDivision of Allergy and Clinical Immunology, Department of Medicine, Jeff and Penny Vinik Center for Translational Immunology Research, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Nicole L MartinBiometrics, Late-Stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA, USA.
Scott CaveneyRespiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.ORCID 0000-0002-2006-5130
Christopher S AmbroseRespiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.ORCID 0000-0003-4175-7336
Neil MartinInstitute for Lung Health, National Institute for Health and Care Research, Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
Joseph D SpahnRespiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA.
Flavia C L HoyteDivision of Allergy and Immunology, National Jewish Health, Denver, CO, USA.ORCID 0000-0002-0426-6362

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTezepelumab blocks the activity of thymic stromal lymphopoietin, an epithelial cytokine implicated in the pathogenesis of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). In a previous analysis, tezepelumab improved asthma and rhinosinusitis symptoms compared with placebo in patients with severe, uncontrolled asthma and a history of CRSwNP in the 2 years before randomization in the NAVIGATOR study. This post hoc analysis of patients with a CRSwNP diagnosis at any time before randomization in NAVIGATOR enabled domain and symptom-specific analyses of Sino-Nasal Outcome Test (SNOT)-22 outcomes.

methodsPatients (aged 12-80 years) with severe, uncontrolled asthma were randomized to tezepelumab 210 mg or placebo subcutaneously every 4 weeks for 52 weeks. SNOT-22 total, domain, and item scores were assessed in patients with a history of CRSwNP. Annualized asthma exacerbation rate (primary efficacy outcome), pre-bronchodilator forced expiratory volume in 1 s, and Asthma Control Questionnaire-6, Asthma Quality of Life Questionnaire (standardized) for patients 12 years and older, and Asthma Symptom Diary scores were also assessed in patients with and without a history of CRSwNP.

resultsOf 1059 patients with severe asthma, 165 (15.6%) had a history of CRSwNP. Tezepelumab treatment resulted in sustained improvements versus placebo in SNOT-22 total score throughout the 52-week study period [least-squares mean difference (95% confidence interval) - 11.08 (- 17.80, - 4.35)]. Tezepelumab improved all five SNOT-22 domain scores (sleep, nasal, function, ear/facial, and emotion) and the five SNOT-22 item scores of most clinical interest (decreased sense of smell/taste, nasal blockage, reduced productivity, waking up tired, and cough). Tezepelumab improved asthma-related clinical outcomes in patients with and without a history of CRSwNP.

conclusionIn patients with severe, uncontrolled asthma and a history of CRSwNP, tezepelumab improved rhinosinusitis symptoms across multiple domains, as well as asthma exacerbations, lung function, asthma control, and health-related quality of life. CLINICALTRIALS: GOV IDENTIFIER: NCT03347279 ( https://classic. CLINICALTRIALS: gov/ct2/show/NCT03347279 ).

Indexed as

Antibodies, Monoclonal, HumanizedAsthmaNasal PolypsRhinitisSinusitisAdolescentAdultAgedAged, 80 and overChildChronic DiseaseDouble-Blind MethodFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedtezepelumabAsthmaBiologicChronic rhinosinusitisNasal polypsSino-Nasal Outcome Test-22TezepelumabThymic stromal lymphopoietin

Identifiers

PMID39514041
PMCPMC11782459

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.